|Bid||11,250.00 x 0|
|Ask||11,256.00 x 0|
|Day's range||10,978.00 - 11,294.00|
|52-week range||8,029.00 - 11,294.00|
|Beta (5Y monthly)||0.12|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||2.22 (2.02%)|
|Ex-dividend date||11 Aug 2022|
|1y target est||N/A|
Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza sNDA.
Merck (MRK) is set to make an upfront payment of $150 million to Orna for rights to the latter's circular RNA technology to make vaccines and therapeutics for infectious disease and oncology.
Pharma group alleges breach of non-compete agreement to delay start date of departing business development official